Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.
Hemodial Int. 2024 Jan;28(1):77-84. doi: 10.1111/hdi.13125. Epub 2023 Oct 24.
Elevated N-terminal pro B-type natriuretic peptide (NT-proBNP) is a potent predictor of adverse outcomes in hemodialysis initiation. These patients often experience intradialytic hypotension, which may partially reflect cardiac dysfunction, but the association of NT-proBNP with intradialytic hypotension is not clear.
We performed a post hoc analysis of a randomized trial that tested mannitol versus placebo in 52 patients initiating hemodialysis (NCT01520207). NT-proBNP was measured prior to the first and third sessions (n = 87). Mixed-effects models (adjusting for randomized treatment, sex, race, age, diabetes, heart failure, catheter use, pre-dialysis systolic blood pressure, pre-dialysis weight, ultrafiltration volume, serum sodium, bicarbonate, urea nitrogen, phosphate, albumin, hemoglobin, and session length) were fit to examine the association of NT-proBNP with systolic blood pressure decline (pre-dialysis minus nadir systolic blood pressure). Additionally, mixed-effects Poisson models were fit to examine the association with intradialytic hypotension (≥20 mmHg decline in systolic blood pressure).
Mean age was 55 ± 16 years; 33% had baseline heart failure. The median NT-proBNP was 5498 [25th-75th percentile 2011, 14,790] pg/mL; 26 sessions (30%) were complicated by intradialytic hypotension. In adjusted models, each unit higher log-NT-proBNP was associated with 6.0 mmHg less decline in systolic blood pressure (95%CI -9.2 to -2.8). Higher pre-dialysis NT-proBNP, per log-unit, was associated with a 52% lower risk of intradialytic hypotension (IRR 0.48, 95%CI 0.23-0.97), without evidence for effect modification by randomized treatment (P-interaction = 0.17).
In patients initiating hemodialysis, higher NT-proBNP is associated with less decline in intradialytic systolic blood pressure and lower risk of intradialytic hypotension. Future studies should investigate if higher pre-dialysis NT-proBNP levels may identify patients who might tolerate more aggressive ultrafiltration.
升高的 N 端脑利钠肽前体(NT-proBNP)是血液透析开始时不良结局的有力预测因子。这些患者经常经历透析中低血压,这可能部分反映了心脏功能障碍,但 NT-proBNP 与透析中低血压的关系尚不清楚。
我们对一项随机试验进行了事后分析,该试验在 52 名开始血液透析的患者中测试了甘露醇与安慰剂(NCT01520207)。在第一次和第三次治疗前测量了 NT-proBNP(n=87)。使用混合效应模型(调整随机治疗、性别、种族、年龄、糖尿病、心力衰竭、导管使用、透析前收缩压、透析前体重、超滤量、血清钠、碳酸氢盐、尿素氮、磷酸盐、白蛋白、血红蛋白和治疗时间)来检查 NT-proBNP 与收缩压下降(透析前减去收缩压最低值)的关系。此外,还拟合了混合效应泊松模型来检查与透析中低血压(收缩压下降≥20mmHg)的关系。
平均年龄为 55±16 岁;33%的患者基线时存在心力衰竭。中位 NT-proBNP 为 5498[25 至 75 百分位数 2011,14790]pg/ml;26 个治疗(30%)并发透析中低血压。在调整后的模型中,每单位更高的 log-NT-proBNP 与收缩压下降 6.0mmHg 相关(95%CI-9.2 至-2.8)。更高的透析前 NT-proBNP 每单位与透析中低血压的风险降低 52%相关(IRR 0.48,95%CI 0.23-0.97),但没有证据表明随机治疗存在效应修饰(P 交互=0.17)。
在开始血液透析的患者中,较高的 NT-proBNP 与透析中收缩压下降较少和透析中低血压风险较低相关。未来的研究应探讨透析前较高的 NT-proBNP 水平是否可以识别可能耐受更积极超滤的患者。